AIM: £4.53 (+0.04) | Nasdaq: $29.22 (-0.06)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
Innovation Platform
Overview
R&D Approach
Our Pipeline
Expanded Access
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Competitive Advantages
Prescription Drugs
Consumer Health
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Financial Results
Overview
Chairman's Statement
Financial Highlights
Financial Reports
SEC Filings
Shareholder Information
Overview
Events, Circulars & Forms
Share Price & Chart
Major Shareholders
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
Terms of Reference & Policies
AIM Rule 26
Careers
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
Innovation Platform
Overview
R&D Approach
Our Pipeline
Expanded Access
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Competitive Advantages
Prescription Drugs
Consumer Health
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Financial Results
Overview
Chairman's Statement
Financial Highlights
Financial Reports
SEC Filings
Shareholder Information
Overview
Events, Circulars & Forms
Share Price & Chart
Major Shareholders
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
Terms of Reference & Policies
Audit Committee – Terms of Reference
AIM Rule 26
Careers
CNBC Street Signs
CEO Christian Hogg discusses plans for surufatinib U.S. NDA submission
Watch Interview
ASCO Investor Update
June 1, 2020 (Mon) | 1pm GMT/ 8am EDT/ 8pm HKT
View Webcast Replay
Surufatinib at AACR 2020
American Association for Cancer Research Virtual Annual Meeting I
View Presentations
Corporate Presentation
Building a global science-focused biopharma from an established base in China
Download Presentation
The Lancet Oncology:
Osimertinib plus Savolitinib in EGFRm+, MET-amplified NSCLC
Read Abstract
AstraZeneca & Chi-Med
Harnessing the power of Chinese scientific innovation
Learn More
Latest News
Group
|
26 Jun 2020
Chi-Med to Announce 2020 Half-Year Financial Results
Group
|
25 Jun 2020
Chi-Med Announces US$100 Million Equity Investment by General Atlantic
Innovation Platform
|
18 Jun 2020
Chi-Med Announces Fruquintinib Granted U.S. FDA Fast Track Designation for Metastatic Colorectal Cancer
Commercial Platform
|
9 Jun 2020
Chi-Med Announces US$95 million Guangzhou Land Compensation Agreement
Innovation Platform
|
4 Jun 2020
Chi-Med Announces the Continuation of Phase III FRUTIGA Study of Fruquintinib in Second-Line Gastric Cancer in China Following a Planned Interim Data Review
Current Share Price
London AIM:HCM
£4.53
+0.04 | 9 Jul 2020 | 15:30
Nasdaq AIM:HCM
US$29.22
-0.06 | 9 Jul 2020 | 10:30
Note: 1 Nasdaq share = 5 AIM shares
Latest Presentations
30 Jun 2020
Corporate presentation
1 Jun 2020
ASCO Investor Update
27 Apr 2020
AACR2020: Comparison of Pharmacokinetic Profiles and Safety of Surufatinib in Patients from China and the United States
Latest Reports
Annual Report 2019 (with Form 20-F)
EN
Interim Report 2019
EN
Annual Report 2018 (with Form 20-F)
EN
Share conversions between AIM & Nasdaq
Mailing list sign-up
Analyst Coverage
The leading China-based innovator
Our
Innovation Platform
focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.
Learn More
A powerful commercial network in China
Our
Commercial Platform
manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.
Learn More